Los Angeles Biosciences, Inc. filed a Form D with the Securities and Exchange Commission on 2025-06-24.
Los Angeles Biosciences, Inc. filed a Form D notice of an exempt securities offering with the SEC on June 24, 2025. The filing reports $4.87M sold. Its industry group is Other Health Care. It names Derya Kelter (Executive Officer, Director), Ketan Patel (Director), Jeff Nichols (Executive Officer) (SEC Form D, June 24, 2025).
Is this your company?
Sell to companies like Los Angeles Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-06-24 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Los Angeles Biosciences, Inc.
Free to see. No signup.
More on the people and the money behind Los Angeles Biosciences, Inc., from the filings we hold.
Other Health Care raises by companies based in California, filed in June 2025, largest first.
Get an email when Los Angeles Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Los Angeles Biosciences, Inc. raises, hires or launches. No email unless you switch it on.
Watch Los Angeles Biosciences, Inc. →Get the full cited report on Los Angeles Biosciences, Inc.
What the filing shows about Los Angeles Biosciences, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Los Angeles Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Los Angeles Biosciences, Inc.'s address as 419 Waterview Street, Playa Del Rey, CA 90293.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Los Angeles Biosciences, Inc. See pricing
Los Angeles Biosciences, Inc. is a registered filer with the SEC (CIK 2074477) and has filed since 2025-06-24. 1 filing is on record, the latest on 2025-06-24.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Los Angeles Biosciences, Inc.'s Form D of 2025-06-24 names Derya Kelter, Ketan Patel and Jeff Nichols as its officers, directors or promoters.
Its new offerings report $4.87M sold across 1 offering, as its own filings state.
Trailing twelve months. 869 filings in Other Health Care, totalled by week.
Derya Kelter is named as Executive Officer and Director on the Form D that Los Angeles Biosciences, Inc. filed with the SEC on 24 June 2025, one of 3 people that filing names.
Ketan Patel is named as Director on the Form D that Los Angeles Biosciences, Inc. filed with the SEC on 24 June 2025, one of 3 people that filing names.
Jeff Nichols is named as Executive Officer on the Form D that Los Angeles Biosciences, Inc. filed with the SEC on 24 June 2025, one of 3 people that filing names.
3 people named on the filing — 2 holding an executive role and 1 as a director only.
Named as of the 2025-06-24 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Los Angeles Biosciences, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Los Angeles Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Los Angeles Biosciences, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Los Angeles Biosciences, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Los Angeles Biosciences, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Los Angeles Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/los-angeles-biosciences-inc-form-d-25000001